Biggest News Aggregation in the World
๐Ÿ“ฐ Beigene News

Page 18 - Beigene News Today

Fast, Ad-Free News Updates

Stay updated with breaking news from Beigene. Real-time updates on events, politics, business and more.

Novartis tislelizumab plus chemotherapy significantly improved overall survival as first-line treatment for advanced esophageal cancer in Phase III study

RATIONALE 306 trial met primary endpoint at interim analysis, demonstrating tislelizumab plus chemotherapy significantly improved overall survival compared to chemotherapy alone in patients with previously untreated advanced esophageal squamous cell carcinoma (ESCC) 1
United States Jeff Legos Drug Administration Global Head Of Oncology Hematology Development Exchange Commission European Medicines Agency

Global Phase 3 Trial of BeiGene's PD-1 Inhibitor, Tislelizumab, in Combination with Chemotherapy Meets Primary Endpoint in First-Line Advanced Esophageal Squamous Cell Carcinoma

Statistically significant and clinically meaningful improvement in overall survival achieved for tislelizumab and chemotherapy compared to placebo and chemotherapy Safety profile for the
United States United Kingdom Great Britain Kevin Mannix Gastrointest Endosc Mark Lanasa

Analysts Anticipate BeiGene, Ltd. (NASDAQ:BGNE) Will Announce Quarterly Sales of $251.05 Million

Equities analysts predict that BeiGene, Ltd. (NASDAQ:BGNE – Get Rating) will report sales of $251.05 million for the current quarter, according to Zacks. Two analysts have provided estimates for BeiGene’s earnings. The highest sales estimate is $287.60 million and the lowest is $214.50 million. BeiGene reported sales of $605.87 million during the same quarter last […]
United States Shaughnessy Asset Management Morgan Stanley Assetmark Inc Zacks Investment Research Deutsche Bank Aktiengesellschaft

BeiGene, Ltd. (NASDAQ:BGNE) Given Average Recommendation of "Hold" by Analysts

Shares of BeiGene, Ltd. (NASDAQ:BGNE – Get Rating) have been given a consensus recommendation of “Hold” by the eight ratings firms that are presently covering the company, MarketBeat reports. Two research analysts have rated the stock with a sell rating, one has assigned a hold rating and five have assigned a buy rating to the […]
United States Beigene Company Profile Get Rating Zacks Investment Research Deutsche Bank Aktiengesellschaft Norges Bank Blackrock Inc

Stay Updated with Latest News

Get breaking news updates delivered to your inbox

Browse All News โ†’

Zacks Investment Research Lowers BeiGene (NASDAQ:BGNE) to Sell

BeiGene (NASDAQ:BGNE – Get Rating) was downgraded by Zacks Investment Research from a “hold” rating to a “sell” rating in a report released on Wednesday, Zacks.com reports. According to Zacks, “BeiGene, Ltd. is a biotechnology company which focused on immuno-oncological therapeutics. The company’s clinical-stage drug candidates include BGB-3111, BGB-283, BGB-290, and BGB-A317. BeiGene, Ltd. is […]
Cayman Islands United States Assetmark Inc Shaughnessy Asset Management Morgan Stanley Zacks Investment Research

IRC Determines BRUKINSA (Zanubrutinib) Demonstrates Superior Overall Response Rate Versus Ibrutinib in Final Response Analysis of ALPINE Trial in Chronic Lymphocytic Leukemia

11.04.2022 - BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global biotechnology company focused on developing and commercializing innovative medicines worldwide, today announced results from the Phase 3 ALPINE trial showing BTK inhibitor BRUKINSA ... Seite 1
United States New Zealand Lai Wang Global Head Of Research Development At Beigene Beigene Ltd Independent Review Committee

Explore More Categories

World News India News Business Technology Sports Entertainment Health Science